tetano
Editor, Senior Moderator
Clin Transl Sci
. 2023 Jun 16.
doi: 10.1111/cts.13569. Online ahead of print. Anticoagulant therapy in COVID-19: A narrative review
Zeinab Mohseni Afshar[SUP] #[/SUP][SUP] 1 [/SUP], Ali Tavakoli Pirzaman[SUP] #[/SUP][SUP] 2 [/SUP], Rezvan Hosseinzadeh[SUP] 2 [/SUP], Arefeh Babazadeh[SUP] 3 [/SUP], Mohamad Ali Taghizadeh Moghadam[SUP] 4 [/SUP], Seyed Rouhollah Miri[SUP] 5 [/SUP], Terence T Sio[SUP] 6 [/SUP], Mark J M Sullman[SUP] 7 8 [/SUP], Mohammad Barary[SUP] 9 [/SUP], Soheil Ebrahimpour[SUP] 3 [/SUP]
Affiliations
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can manifest itself in several ways, including coagulopathy and thrombosis. These complications can be the first and sometimes only manifestations of SARS-CoV-2 infection and can occur early or late in the course of the disease. However, these symptoms are more prevalent in hospitalized venous thromboembolism (VTE) patients, particularly those admitted to intensive care units (ICUs). Moreover, various forms of arterial and venous thrombosis, or micro- or macro-vasculature embolisms, have been reported during the current pandemic. They have led to harmful consequences, such as neurological and cardiac events, nearly all resulting from the hypercoagulable state caused by this viral infection. The severe hypercoagulability observed in COVID-19 patients accounts for most cases of the disease that become critical. Therefore, anticoagulants seem to be one of the most vital therapeutics for treating this potentially life-threatening condition. In the current article, we present a thorough review of the pathophysiology of COVID-19-induced hypercoagulable state and the use of anticoagulants to treat SARS-CoV-2 infections in different patient groups, as well as their pros and cons.
. 2023 Jun 16.
doi: 10.1111/cts.13569. Online ahead of print. Anticoagulant therapy in COVID-19: A narrative review
Zeinab Mohseni Afshar[SUP] #[/SUP][SUP] 1 [/SUP], Ali Tavakoli Pirzaman[SUP] #[/SUP][SUP] 2 [/SUP], Rezvan Hosseinzadeh[SUP] 2 [/SUP], Arefeh Babazadeh[SUP] 3 [/SUP], Mohamad Ali Taghizadeh Moghadam[SUP] 4 [/SUP], Seyed Rouhollah Miri[SUP] 5 [/SUP], Terence T Sio[SUP] 6 [/SUP], Mark J M Sullman[SUP] 7 8 [/SUP], Mohammad Barary[SUP] 9 [/SUP], Soheil Ebrahimpour[SUP] 3 [/SUP]
Affiliations
- PMID: 37326220
- DOI: 10.1111/cts.13569
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can manifest itself in several ways, including coagulopathy and thrombosis. These complications can be the first and sometimes only manifestations of SARS-CoV-2 infection and can occur early or late in the course of the disease. However, these symptoms are more prevalent in hospitalized venous thromboembolism (VTE) patients, particularly those admitted to intensive care units (ICUs). Moreover, various forms of arterial and venous thrombosis, or micro- or macro-vasculature embolisms, have been reported during the current pandemic. They have led to harmful consequences, such as neurological and cardiac events, nearly all resulting from the hypercoagulable state caused by this viral infection. The severe hypercoagulability observed in COVID-19 patients accounts for most cases of the disease that become critical. Therefore, anticoagulants seem to be one of the most vital therapeutics for treating this potentially life-threatening condition. In the current article, we present a thorough review of the pathophysiology of COVID-19-induced hypercoagulable state and the use of anticoagulants to treat SARS-CoV-2 infections in different patient groups, as well as their pros and cons.